Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The results will be published in health or scientific journals, on websites (including and and will be discussed at major conferences. Others will learn from the results, which we hope will show that more lives can be saved by using empagliflozin. No individual participant will be identified in any report or publication.

We will try our best to inform participants and their GPs of the study results, and any related publicity. We will use study newsletters and videos on the study’s website to inform people about what the study shows.

Participants' contribution to the study could be even more valuable if we have their permission to get information about their health after the very last study appointment. This way we can learn about any longer-term health effects of the study pills. This might include a questionnaire or phone call once a year. Also, the study scientists can continue to get information about participants' health, such as details from local doctors, NHS England (or other central NHS registry) and the UK Renal Registry.